Get the Stockscreener App
25.20
0.76%
0.1894
Moderna Inc stock is traded at $25.20, with a volume of 798.49K.
It is up +0.76% in the last 24 hours and down -0.60% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$25.01
Open:
$25.01
24h Volume:
798.49K
Relative Volume:
0.07
Market Cap:
$9.86B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.8865
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+6.24%
1M Performance:
-0.60%
6M Performance:
-3.27%
1Y Performance:
-41.92%
1-Day Range:
$24.87
$25.25
1-Week Range:
$23.55
$25.32
52-Week Range:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.23 | 9.77B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
430.95 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.95 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.40 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
909.49 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.90 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Legal & General Group Plc Sells 845,459 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Take Profit: How buybacks impact Moderna Inc. stock valueJuly 2025 Macro Moves & Weekly Setup with ROI Potential - BỘ NỘI VỤ
Jefferies Financial Group Inc. Sells 109,640 Shares of Moderna, Inc. $MRNA - MarketBeat
Where Will Vertex Pharmaceuticals Be in 5 Years - The Motley Fool
Handelsbanken Fonder AB Sells 62,447 Shares of Moderna, Inc. $MRNA - MarketBeat
Ensign Peak Advisors Inc Has $3.42 Million Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Announces Data to be Presented at ESMO Congress 2025 - Montgomery Advertiser
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - Daytona Beach News-Journal
Berenberg Trims Price Target on Moderna to $26 From $28, Keeps Hold Rating - MarketScreener
(MRNA) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Moderna, Inc. $MRNA Shares Sold by Nomura Asset Management Co. Ltd. - MarketBeat
Moderna exec explains shift to onshore manufacturing, Norwood investment - The Business Journals
Entropy Technologies LP Invests $552,000 in Moderna, Inc. $MRNA - MarketBeat
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - Independent Mail
Moderna (MRNA) Secures $1.5 Billion Credit Facility to Bolster C - GuruFocus
Moderna Secures $1.5 Billion Credit Facility - TipRanks
Moderna, Inc. Enters into Credit Agreement - MarketScreener
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo Finance UK
Moderna is the S&P 500's most shorted stock: Here's why - Yahoo Finance
Transcript : Moderna, Inc.Analyst/Investor Day - MarketScreener
Moderna : Transcript (MRNA USQ Transcript 2025 11 20 2) - MarketScreener
Vanguard Group Inc. Buys 1,312,192 Shares of Moderna, Inc. $MRNA - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Reduces Position in Moderna, Inc. $MRNA - MarketBeat
Phenomenal Value Destruction at Moderna - MarketScreener
Moderna presents pipeline progress and 3-year strategy - MarketScreener
US vaccine skepticism hits Moderna stock - https-//www.semafor.com
Creative Planning Increases Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Gaston Gazette
How Recent Developments Are Rewriting the Story for Moderna - Yahoo Finance
First-Ever Human H5N5 Case Turns Fatal In Washington StateModerna (NASDAQ:MRNA), Pfizer (NYSE:PFE) - Benzinga
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates - The Oklahoman
Leerink Partners Issues Positive Forecast for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Royal Bank Of Canada Lowers Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat
Moderna stock remains Buy at UBS as analyst sees strong pipeline progress - Investing.com Canada
Leerink Partners Maintains Moderna (MRNA) Underperform Recommendation - Nasdaq
RBC Capital Maintains Moderna (MRNA) Sector Perform Recommendation - Nasdaq
Clover Health, GoodRx, Moderna, UFP Technologies, and Masimo Shares Are Soaring, What You Need To Know - The Globe and Mail
Moderna (NASDAQ:MRNA) Sets New 12-Month LowHere's Why - MarketBeat
Five Things To Know From Moderna’s Analyst Day - Citeline News & Insights
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Tallahassee Democrat
Piper Sandler Lowers Moderna (MRNA) Price Target to $63 | MRNA Stock News - GuruFocus
Moderna (MRNA) Rating Maintained, Price Target Lowered by RBC Ca - GuruFocus
MRNA: Leerink Partners Raises Price Target, Maintains Underperfo - GuruFocus
Piper Sandler Adjusts Price Target on Moderna to $63 From $69, Maintains Overweight Rating - MarketScreener
Leerink Partners Adjusts Price Target on Moderna to $18 From $15, Maintains Underperform Rating - MarketScreener
RBC Cuts Price Target on Moderna to $25 From $28, Keeps Sector Perform Rating - MarketScreener
Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth - BioSpace
$1.5 Billion Loan Aims to Help Moderna Grow and Invest in Research - MarketScreener
Rx Rundown: Johnson & Johnson, Avadel Pharmaceuticals, Moderna and more - Medical Marketing and Media
Analyst recommendations: Block, Palo Alto Networks, Biogen, Moderna, Netflix… - MarketScreener
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):